LGVN
Longeveron Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.49
−8.12%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.73
From 52W high−70.53%
Volume518963.00
Market cap$7.94M
P/E (TTM)—
P/S (TTM)6.7x
Div yield—
Key dataSep 18, 2026
Open
$2.73
From 52W high
−70.53%
Volume
518963.00
Market cap
$7.94M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
24.7
MomentumView details →
1D Return
−8.12%
YTD Return
+370.36%
SummaryUpdated Jun 1, 2026
Longeveron Inc. (NASDAQ:LGVN) is a clinical-stage biotechnology company founded in 2014 and based in Miami, Florida. The company went public in February 2021 and focuses on developing cellular therapies for aging-related and life-threatening conditions. Longeveron's primary focus is advancing its lead investigational product, LOMECEL-B, a cell-based therapy derived from bone marrow of young healthy adult donors, through various clinical trials targeting rare diseases and age-related conditions.
Similar companies
Latest newsMore news →
Longeveron said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.4d agoLongeveron Inc. announced a 1-for-10 reverse split of its Class A and Class B common stock, previously approved by stockholders on July 1, 2026 and by the board on July 31, 2026.27d ago